Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02660281 · ClinicalTrials.gov registry record · Phase 1
URMC Related Haplo-identical Donor BMT
A Phase 1 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
NCT02660281 is a Phase 1 study that has completed, run by University of Rochester. The registered enrollment target is 74 participants.
The verdict
NCT02660281, a Phase 1 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
Study Summary
This study will be a single-center treatment protocol, designed to validate the process of related donor haploidentical-SCT at the Wilmot Cancer Institute Blood and Marrow Transplant Unit.
Interventions
- DRUG Fludarabine
- DRUG Busulfan
- RADIATION Total Body Irradiation 1200 cGy
- DRUG Pre-Stem Cell Infusion Cyclophosphamide
- DRUG Pre-Stem Cell Infusion Mesna
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2015-10 |
| Est. Completion | 2021-01-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02660281
The ClinicalTrials.gov registry entry for NCT02660281 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT02660281 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02660281 about?
NCT02660281 is a clinical study titled "URMC Related Haplo-identical Donor BMT". This study will be a single-center treatment protocol, designed to validate the process of related donor haploidentical-SCT at the Wilmot Cancer Institute Blood and Marrow Transplant Unit.
What is the current status of trial NCT02660281?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2015-10. Estimated completion is 2021-01-07.
What interventions are being tested in trial NCT02660281?
The interventions under investigation include: Fludarabine (DRUG), Busulfan (DRUG), Total Body Irradiation 1200 cGy (RADIATION), Pre-Stem Cell Infusion Cyclophosphamide (DRUG), Pre-Stem Cell Infusion Mesna (DRUG).
Who is sponsoring clinical trial NCT02660281?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.